Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 6.5 Contact Hours.
Acknowledgment of Commercial SupportThis activity is supported by educational grants from AstraZeneca, Foundation Medicine, Inc., Genentech, Incyte, Merck Sharp & Dohme Corp. and NantHealth, Inc.
1st Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application
Saturday, December 10, 2016
Crowne Plaza® Times Square Manhattan
1605 Broadway (at 49th Street)
New York, NY 10019
The development of immunotherapies to treat cancer has transformed the way clinicians think about managing their patients with many forms of malignancies. The speed, at which basic science and clinical trial information continues to emerge in this area, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the-art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.
"But, how do I use this information to manage my patients with cancer?"
This is the key question, and the one whose answer ultimately means the most to your patients. The International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application will do just that, by answering that question. This exciting, fast-paced, and interactive Congress will provide a focused, multi-module curriculum-based program, exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will provide a comprehensive review of key data sets, most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings, and the most highly anticipated clinical trials in the field.
This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on the immunotherapies, and their evolving roles in the treatment of cancer.
At the conclusion of this activity, participants should be better prepared to:
- Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer.
- Evaluate clinical trial findings on immuno-oncology strategies and how they can be practically applied to the management of cancer in multiple lines of care.
- Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies.
- Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed.
- Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies.
Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery
Professor of Molecular & Medical Pharmacology
David Geffen School of Medicine
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California, USA
Naiyer A. Rizvi, MD
Director, Thoracic Oncology
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
You must be logged in to PER to register for this meeting
Or Register for PER now